MBX - Mbx Biosciences, Inc.

Insider Purchase by Hawryluk P. Kent (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Hawryluk P. Kent, serving as Pres, CEO at Mbx Biosciences, Inc. (MBX), purchased 18,500 shares at $28.41 per share, for a total transaction value of $525,663.00. Following this transaction, Hawryluk P. Kent now holds 1,215,051 shares of MBX.

This purchase represents a 2.00% increase in Hawryluk P. Kent's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, March 13, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 16, 2026, 3 days after the trade was made.

Mbx Biosciences, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Hawryluk P. Kent

Hawryluk P. Kent

Pres, CEO

P. Kent Hawryluk (age 56) is the co-founder, President, Chief Executive Officer, and Director of MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on developing peptide therapeutics for endocrine and metabolic diseases.[[1]](https://fintool.com/app/research/companies/MBX/people/p-kent-hawryluk)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/management)[[5]](https://mbxbio.com/about-us/) He has served as CEO since January 2020 and as a director since April 2019, leading key milestones such as completing enrollment in the Phase 2 Avail trial for canvuparatide, positive Phase 1 results for MBX 1416, and planning an IND for MBX 4291 in Q2 2025.[[1]](https://fintool.com/app/research/companies/MBX/people/p-kent-hawryluk) Hawryluk owns approximately 2.52-5.69% of the company and received total compensation of $2.24M in the latest reported year.[[1]](https://fintool.com/app/research/companies/MBX/people/p-kent-hawryluk)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/management) Hawryluk brings over 20 years of experience as a life sciences entrepreneur, leader, and investor.[[3]](https://www.zoominfo.com/p/Kent-Hawryluk/9007493405)[[4]](https://www.bio.org/events/bio-international-convention/speakers/1974308)[[5]](https://mbxbio.com/about-us/) His career highlights include co-founding and serving as Chief Business Officer at Avidity Biosciences (2013–2019), where he built RNA therapeutics and business development capabilities; co-founding and leading MB2 LLC as CEO (2014–2016), acquired by Novo Nordisk; and co-founding Marcadia Biotech as CBO and VP of Business Development (2006–2011), acquired by Roche.[[1]](https://fintool.com/app/research/companies/MBX/people/p-kent-hawryluk)[[4]](https://www.bio.org/events/bio-international-convention/speakers/1974308) He holds a B.A. from Princeton University, an M.B.A. from Northwestern University’s Kellogg School of Management, and an M.S. in Biology from Purdue University.[[1]](https://fintool.com/app/research/companies/MBX/people/p-kent-hawryluk)[[4]](https://www.bio.org/events/bio-international-convention/speakers/1974308) Additionally, he is a Partner at Twilight Venture Partners since 2003 and previously served as a director at Gemphire Therapeutics (2015–2019).[[1]](https://fintool.com/app/research/companies/MBX/people/p-kent-hawryluk)

View full insider profile →

Trade Price

$28.41

Quantity

18,500

Total Value

$525,663.00

Shares Owned

1,215,051

Trade Date

Friday, March 13, 2026

5 days ago

SEC Filing Date

Monday, March 16, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Mbx Biosciences, Inc.

Company Overview

No company information available
View news mentioning MBX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4828951

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime